New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Check below for free stories on CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 16, 2014
14:33 EDTNKTRNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
13:41 EDTVRTXVertex price target raised to $126 from $103 at Deutsche Bank
Subscribe for More Information
13:22 EDTNKTRNektar approval improves risk/reward, says Piper Jaffray
Piper Jaffray says today's FDA approval of Movantik improves the risk/reward on shares of Nektar. Piper expects Movantik to be one of a series of successes for the company and reiterates an Overweight rating on the stock with a $20 price target. The firm says the post-marketing study required by the FDA to evaluate potential cardiovascular risks was expected.
13:17 EDTNKTRNektar up 3% after FDA approves Movantik for treatment of OIC
Subscribe for More Information
12:37 EDTNKTRNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
11:56 EDTPBRStocks with call strike movement; PBR SCTY
Petrobras (PBR) January 20 call option implied volatility increased 2% to 54, SolarCity (SCTY) January 80 call option implied volatility increased 3% to 53 according to IVolatility.
10:19 EDTNKTRFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
10:11 EDTNKTRNektar trading halted, pending news
09:36 EDTPBRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
08:00 EDTNKTRFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:31 EDTJNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:26 EDTCATUltima Media to hold a conference
Subscribe for More Information
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
05:52 EDTPBRStocks with implied volatility top IV index mean; TAP PBR
Subscribe for More Information
September 15, 2014
11:51 EDTJCPStocks with call strike movement; TWTR JCP
Twitter (TWTR) November 57.50 call option implied volatility increased 4% to 54, J.C. Penney (JCP) October 12 call option implied volatility increased 8% to 52 according to IVolatility.
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 12, 2014
16:00 EDTPBROptions Update; September 12, 2014
Subscribe for More Information
11:51 EDTPBRStocks with call strike movement; PBR GPRO
Subscribe for More Information
10:05 EDTPBRPetrobras volatility elevated on wide price movement
Subscribe for More Information
09:37 EDTPBRActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use